Clinical trials: Atherosclerotic Cardiovascular Disease (ASCVD), open to volunteers
Atherosclerotic Cardiovascular Disease (ASCVD), Hypertension
Evaluation of an Integrated, Digital, Nurse-led, Remote Monitoring Care Pathway for Cardiovascular Risk Management
The goal of this observational study is to evaluate the implementation of a structured, digital, nurse-led, remote monitoring care pathway for cardiovascular risk management (CVRM).
- Conditions
- Atherosclerotic Cardiovascular Disease (ASCVD), Hypertension, Dyslipidemia
- Trial name
- TELE-CVRM (NCT07208331)
- Where
- Netherlands
- Volunteers
- 750 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Hyperlipidemia, Atherosclerotic Cardiovascular Disease (ASCVD)
PCSK9 Inhibitors in Hyperlipidemia and Atherosclerosis
PCSK9 inhibitors, including evolocumab and alirocumab, are lipid-lowering therapies used in patients with hyperlipidemia and atherosclerotic cardiovascular disease.
- Trial name
- NCT07856264
- Volunteers
- 100 people
- Sponsor
- Fundación Santa Fe de Bogota
Elevated Lp(a), Atherosclerotic Cardiovascular Disease (ASCVD)
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
The purpose of this study is to evaluate the efficacy of muvalaplin in reducing cardiovascular risk in participants with high lipoprotein(a) who have cardiovascular disease or are at risk of a heart attack or stroke.
- Trial name
- MOVE-Lp(a) (NCT07157774)
- Testing
- Muvalaplin
- Where
- 804 sites in United States, Argentina and 26 more
- Volunteers
- 10,450 people
- Sponsor
- Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Cardiovascular Risk
LDL Cholesterol Reduction Following Ezetimibe Initiation
This clinical trial will study why some people have a larger drop in low-density lipoprotein cholesterol (LDL-C), known as "bad cholesterol," after starting ezetimibe.
- Conditions
- Atherosclerotic Cardiovascular Disease (ASCVD), Cardiovascular Risk, LDL Cholesterol
- Trial name
- EZE-TRACK (NCT07839741)
- Testing
- Ezetimibe
- Where
- Portugal
- Volunteers
- 100 people
- Sponsor
- Universidade do Porto
Atherosclerotic Cardiovascular Disease (ASCVD), Erectile Dysfunction
Phase IIa Clinical Trial of YN001 in Patients With Atherosclerotic Cardiovascular and Cerebrovascular Diseases and Erectile Dysfunction
This is a randomized, double-blind, placebo-controlled phase IIa clinical trial to evaluate the efficacy and safety of YN001 in patients with atherosclerotic cardiovascular and cerebrovascular diseases and erectile dysfunction
- Trial name
- NCT07311330
- Testing
- YN001 20mg Dose + 5% glucose injection, 5% glucose injection
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Beijing Inno Medicine Co., Ltd.
Non-communicable Diseases (NCD), Neoplams
Health for Hungary (H4H) - Longitudinal Collection of Blood Samples and Corresponding Data
The Health for Hungary (H4H) study collects blood samples and corresponding health data to investigate healthy aging and health-to-disease transitions in middle-aged and elderly participants.
- Conditions
- Non-communicable Diseases (NCD), Neoplams, Cancer, Lung Cancer (NSCLC)
- Trial name
- H4H (NCT07743021)
- Where
- 33 sites in Hungary
- Volunteers
- 15,000 people, healthy volunteers welcome
- Sponsor
- Center for Molecular Fingerprinting Research Nonprofit LLC
Rheumatoid Arthritis (RA, Atherosclerotic Cardiovascular Disease (ASCVD)
The Coronary Artery Calcium and Troponins in Rheumatoid Arthritis (CAT-RA) Study
Individuals with rheumatoid arthritis (RA) have up to 2x the risk of having a heart attack compared to someone without RA. The goal of this study is to identify biomarkers that can help us do a better job of identifying…
- Trial name
- CAT-RA (NCT07315997)
- Testing
- high sensitivity cardiac troponin
- Where
- 3 sites in United States
- Volunteers
- 120 people
- Sponsor
- Brigham and Women's Hospital
Chronic Kidney Disease Mineral and Bone Disorder, Hypertension
Reducing Inflammation to Improve Vascular and Bone Outcomes With Low-dose Colchicine in CKD
The overall objective of this pilot randomized clinical trial is to determine whether low-dose Colchicine (LoDoCo) improves vascular disease including vascular calcification, peripheral arterial disease (PAD), and chronic kidney…
- Conditions
- Chronic Kidney Disease Mineral and Bone Disorder, Hypertension, Diabetes, Dyslipidemia
- Trial name
- RESOLVE-CKD (NCT07654231)
- Testing
- Low-dose Colchicine at 0.5mg daily, Usual Care
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Texas Southwestern Medical Center
Hypercholesterolemia, Atherosclerotic Cardiovascular Disease (ASCVD)
Dual PCSK9 Inhibition With Inclisiran and Alirocumab in Secondary Prevention
This study will evaluate the effectiveness and safety of combining two different types of PCSK9 inhibitors, inclisiran and alirocumab, in patients with high cardiovascular risk who are unable to tolerate statins.
- Trial name
- PCSK9-DUO (NCT07581808)
- Testing
- Inclisiran, Alirocumab
- Where
- Slovenia
- Volunteers
- 60 people
- Sponsor
- University Medical Centre Ljubljana
Atherosclerotic Cardiovascular Disease (ASCVD)
Target-Oriented Strategy of Ultra-Low LDL-C (<1.0 vs. 1.0-1.39 mmol/L) in Extreme-High-Risk ASCVD Patients: Clinical Benefit, Safety and Cost-Effectiveness Assessment
The goal of this clinical trial is to learn whether an ultra-low LDL-C target (<1.0 mmol/L) can improve clinical outcomes compared with a moderately low LDL-C target (1.0-1.39 mmol/L) in Chinese patients with extreme-high-risk…
- Trial name
- TARGET-EXTREME (NCT07615296)
- Testing
- Lipid-lowering therapy targeting LDL-C <1.0 mmol/L, Lipid-lowering therapy targeting LDL-C 1.0-1.39 mmol/L
- Where
- China
- Volunteers
- 6,000 people
- Sponsor
- Beijing Anzhen Hospital
Atherosclerotic Cardiovascular Disease (ASCVD), Coronary Artery Calcification
Health Enhanced Artery Risk Tracking With Widespread Implementation and Screening Effort in ASCVD (HEARTWISE-ASCVD)
This multi-site study will test whether an opportunistic AI-based CAC screening and notification intervention can improve cholesterol treatment and lower cholesterol levels in adults.
- Trial name
- HEARTWISE (NCT07355894)
- Testing
- AI-Detected CAC Notification and Care Facilitation
- Where
- 6 sites in United States
- Volunteers
- 120,000 people
- Sponsor
- Stanford University
Atherosclerotic Cardiovascular Disease (ASCVD), Secondary Prevention
Aspirin 50 mg vs. 100 mg in Elderly Cardiovascular Disease Patients
Elderly patients with cardiovascular disease face a high risk of both thrombotic and bleeding events when receiving antithrombotic therapy.
- Conditions
- Atherosclerotic Cardiovascular Disease (ASCVD), Secondary Prevention, Cardiovascular Diseases
- Trial name
- LAPIS (NCT07542860)
- Where
- China
- Volunteers
- 5,448 people
- Sponsor
- Peking University First Hospital
Familial Hypercholesterolemias, Atherosclerotic Cardiovascular Disease (ASCVD)
Study of the Determinants of Coronary Atherosclerosis in Familial Hypercholesterolemia (ATHERO-FH Study)
The goal of this study (interventional clinical research not involving a health product) is to assess the prevalence of subclinical coronary atherosclerosis diagnosed by coronary CT angiography in heart failure patients in…
- Trial name
- ATHERO-FH (NCT06960902)
- Testing
- Coronary CT scan with CAC score measurement
- Where
- 9 sites in France
- Volunteers
- 600 people
- Sponsor
- Nantes University Hospital
Atherothrombotic Diseases, Atherosclerotic Cardiovascular Disease (ASCVD)
Polypill and Colchicine for Risk Reduction in Atherosclerotic Cardiovascular Disease
The EPOCA study (Evaluation of a POlypill and Colchicine for risk reduction in patients with established Atherosclerotic cardiovascular disease) will be a randomized, superiority, parallel, 2x2 factorial, multicenter clinical…
- Trial name
- EPOCA (NCT06930885)
- Testing
- Cardiovascular Polypill (Valsartan, Atorvastatin, Aspirin), Colchicine 0.5 mg, Usual Care Group
- Where
- 13 sites in Brazil
- Volunteers
- 7,713 people
- Sponsor
- Hospital do Coracao